We recently reported that the dual-specificity AKAP (A-kinaseanchoring protein) Ezrin targets type I PKA (protein kinase A) to the vicinity of the TCR (T-cell receptor) in T-cells and, together with PAG (phosphoprotein associated with glycosphingolipid-enriched membrane microdomains) and EBP50 [ERM (Ezrin/Radixin/Moesin)-binding phosphoprotein 50], forms a scaffold that positions PKA close to its substrate, Csk (C-terminal Src kinase). This complex is important for controlling the activation state of T-cells. Ezrin binds the adaptor protein EBP50, which again contacts PAG. In the present study, we show that Ezrin and EBP50 interact with high affinity (K D =58 + − 7 nM). A peptide corresponding to the EB (Ezrin-binding) region in EBP50 (EBP50 pep ) was used to further characterize the binding kinetics and compete the Ezrin-EBP50 interaction by various methods in vitro. Importantly, loading T-cells with EBP50 pep delocalized Ezrin, but not EBP50. Furthermore, disruption of this complex interfered with cAMP modulation of T-cell activation, which is seen as a reversal of cAMP-mediated inhibition of IL-2 (interleukin 2) production, demonstrating an important role of EBP50 in this complex. In summary, both the biochemical and functional data indicate that targeting the Ezrin-EBP interaction could be a novel and potent strategy for immunomodulation.
INTRODUCTION
cAMP is an ubiquitous second messenger that mediates signal cues from a multitude of G-protein-coupled receptors and acts through effector molecules, such as type I and type II PKA (protein kinase A), as well as cAMP-regulated guaninenucleotide-exchange factors and ion channels (for review and references, see [1] ). In the immune system, cAMP is a mediator of inflammatory and migratory signals and potently suppresses immune functions in lymphocytes [2] . In effector T-cells cAMP acts through type I PKA to rapidly intersect TCR (T-cell receptor) signalling proximally through a pathway that involves PKAmediated activation of Csk (C-terminal Src kinase), leading to inhibition of the Src family kinases Lck and Fyn that convey the TCR signal [3] . However, robust T-cell immune responses require activation of both the TCR and the co-receptor CD28 which recruits PDE4 (phosphodiesterase 4) to the lipid raft, leading to degradation of the local cAMP pool and counteracting this negative regulatory pathway [4] .
We have reported that Ezrin is an AKAP (A-kinaseanchoring protein) that serves to position type I PKA close to its substrate, Csk, in the lipid raft fraction of the T-cell membrane [5, 6] . In resting T-cells, Csk is anchored to PAG (phosphoprotein associated with glycosphingolipidenriched membrane microdomains) [7, 8] . Activation of Csk by PKA phosphorylation leads to a 2-4-fold increase in Csk activity [3] . This negative regulatory pathway appears to have a function in controlling the activation state of the T-cell, and fine tuning of T-cell signalling by the PKA-Csk-Lck inhibitory pathway is important in avoiding hypo-and hyper-reactivity, the former potentially leading to immunodeficiency and the latter to autoimmunity [9] [10] [11] [12] . Interestingly, the PKA-Csk-Lck inhibitory pathway is spatially organized by a scaffold formed by the AKAP Ezrin and the Csk-binding protein PAG interconnected via the linker protein EBP50 [ERM (Ezrin/Radixin/Moesin)-binding phosphoprotein 50]. The Ezrin-EBP50-PAG anchoring complex positions PKA in proximity to Csk and provides the necessary spatiotemporal resolution of cAMP regulation of Csk and Lck by PKA, as shown from siRNA (small interfering RNA) knockdown and reconstitution experiments in primary T-cells [5, 6] .
Signalling specificity by the ubiquitously expressed type I and type II PKA enzymes is achieved largely through the interaction with AKAPs that, by anchoring PKA at defined subcellular locations, targets the enzyme towards specific substrates, thereby providing necessary spatiotemporal resolution for effective cAMP regulation [13, 14] . AKAPs also assemble multicomponent signalling complexes for allowing cross-talk between different signalling pathways. Ezrin belongs to the ERM family of proteins which play important structural and regulatory roles in linking the plasma membrane to the cytoskeleton through their binding to F-actin (for review, see [15] ). At the N-terminal region of Ezrin is the FERM (N-terminal 4.1 ERM) domain which is highly conserved within the ERM family and also contains the binding site for EBP50. This domain is followed by a less Abbreviations used: AKAP, A-kinase-anchoring protein; AlphaScreen, amplified luminescence proximity homogeneous assay screen; b, biotin-labelled; 8-CPT-cAMP, 8-(4-chlorophenylthio)-cAMP; Csk, C-terminal Src kinase; DTT, dithiothreitol; EB domain, Ezrin-binding domain; ERM, Ezrin/Radixin/Moesin; EBP50, ERM-binding phosphoprotein 50; FERM domain, N-terminal 4.1 ERM domain; FP, fluorescence polarization; GST, glutathione transferase; IL-2 interleukin 2; IS, immunological synapse; PAG, phosphoprotein associated with glycosphingolipid-enriched membrane microdomains; PKA, protein kinase A; RI, type I regulatory subunit; SMC, small molecular compound; SPR, surface plasmon resonance; TCR, T-cell receptor. 1 Present address: Department of Biochemistry, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway. 2 To whom correspondence should be addressed (email kjetil.tasken@biotek.uio.no).
conserved region, mainly comprising α-helixes, whereas the binding site for F-actin is at the C-terminus. Moreover, Ezrin is a dual-specificity AKAP, anchoring both type I and type II PKA [6] , and, in lipid rafts, Ezrin is anchored via the transmembrane proteins CD44/CD43 [16, 17] and EBP50 [6, 18, 19] . Ezrin exists in two conformations: an active open conformation and a dormant closed conformation where the C-terminal domain folds back and binds tightly to the FERM domain, masking several of its activities, including the binding of EBP50 (for review, see [15] ). Phosphorylation of Thr 567 by PKC (protein kinase C) and Rhokinase (for review, see [20] ) favours the open conformation, resulting in unmasking of the binding site for EBP50. EBP50, also known as a NHERF (Na + /H + -exchanger regulatory factor), is a scaffolding protein comprising two PDZ domains and a Cterminal domain, the EB (Ezrin-binding) domain, which binds the ERM family of proteins via the FERM domain [21, 22] . Furthermore, the solution of the structure of a 28-amino-acid peptide from the EB domain in complex with the ERM protein Radixin defined several critical molecular interactions suitable for perturbation [23] . The EBP50 PDZ domains are involved in binding a multitude of different ligands, including PAG [18, 19] .
We have previously investigated the role of Ezrin in T-cell signalling and activation, more specifically the role of type I PKA anchoring via Ezrin [6] . In this context, a RIAD [RI (type I regulatory subunit)-specific anchoring disruptor] peptide successfully displaced type I PKA from the lipid rafts, which resulted in increased downstream TCR signalling through reduced phosphorylation of Tyr 505 of Lck [24] . Moreover, knockdown of Ezrin in T-cells, followed by activation of these cells, reduced their sensitivity to cAMP/PKA-mediated inhibition of IL-2 (interleukin 2) production as compared with control cells [6] . Lastly, Ezrin contains an RISR (RI-specifier region) that serves as an additional binding determinant and increases the specificity for binding type I PKA [5] .
In the present work, our aim was to address in more detail the characteristics of the Ezrin-EBP50 interaction and explore the possibility of perturbing immune inhibition through the PKAEzrin-EBP50-PAG-Csk signalling complex to reverse cAMPmediated immune suppression. Using a variety of biochemical assays we characterized the kinetics of the Ezrin-EBP50 interaction. Furthermore, loading of T-cells with a cell-permeant disruptor peptide of the EB domain in EBP50 (EBP50 pep ) displaced Ezrin, as shown in immunolocalization studies, and reversed the cAMP/PKA-mediated inhibition of T-cell activation. This indicates that perturbation of the PKA-Ezrin-EBP50-PAGCsk signalling complex at the level of EBP50 to separate Csk bound to PAG from PKA bound to Ezrin specifically interferes with cAMP immunomodulation.
EXPERIMENTAL

Constructs
Full-length Ezrin with the T567D activating mutation [6, 25, 26] was cloned into the pRSET vector for expression with a His 6 tag. Full-length EBP50 was cloned into the pGEX vector and expressed as GST (glutathione transferase)-fusion protein. The constructs were confirmed by sequencing.
Peptide synthesis
Peptides were synthesized on a MultiPep automated peptide synthesizer (Intavis Bioanalytical Instruments, Koeln, Germany). The peptides were: EBP50 pep * , KERAHQKRSSKRAPQMDW-SKKNELFSNL; EBP50 ctr pep * , KERAHQKRSSKRAPQMDAS-KANELASNL (control peptide); Arg 9 -EBP50 pep ,RRRRR-RRRRSSKRAPQMDWSKKNELFSNL; and Arg 9 -EBP50 ctr pep , RRRRRRRRRSSKRAPQMDASKANELASNL (control peptide) [23] . The purity and mass were analysed by HPLC and MS. The peptides were dissolved in PBS and the concentration was determined using a Biochrom 30 amino acid analyser (Biochrom, Cambridge, U.K.).
Protein expression and purification
GST-fused full-length EBP50 was expressed in the Escherichia coli strain BL21, and purified using reduced glutathione-agarose beads (Sigma-Aldrich). His 6 -tagged Ezrin-T567D was expressed in the E. coli Rosetta strain and purified by nickel affinity gel chromatography (Sigma-Aldrich). For the SPR (surface plasmon resonance) measurements, an additional gel-filtration step using a Superdex 200 column (GE Healthcare Life Sciences, Uppsala, Sweden) was included for His 6 -Ezrin-T567D.
His 6 -Ezrin-T567D was biotinylated according to the manufacturer's protocol (Pierce Biotechnology, Rockford, IL, U.S.A.). Excess biotin was removed by passing the protein over a NAP-5 column (GE Healthcare Life Sciences) followed by gel filtration on a Superdex 200 column. Protein concentrations were determined using the Bradford protein assay using BSA as a standard and purity was assessed by SDS/PAGE.
SPR studies
The SPR studies were conducted using a Biacore T100 biosensor system (Biacore Life Sciences, GE Healthcare Life Sciences). All interaction studies were carried out at 25
• C in running buffer comprising 10 mM Hepes (pH 7.4), 150 mM NaCl, 3 mM EDTA and 0.05 % (v/v) Surfactant P20 (HBS-EP). GST-EBP50 was captured on to an anti-GST-antibody-coated dextran surface to approx. 450 response units using the CM5 chip and the GST capture kit from Biacore Life Sciences. The analyte (Ezrin-T567D) was injected over the EBP50 surface and binding was measured in running buffer at a flow rate of 50 μl/min for 240 s. The surface was regenerated after each cycle by using 10 mM glycine/HCl, pH 2.2, leaving only a 'naked' anti-GST-antibody surface for a new capture cycle. Equimolar amounts of GST were captured to the reference channel. The binding curves were analysed using the software package from Biacore and Sigma Plot (SPSS, Chicago, IL, U.S.A.).
FP (fluorescence polarization) studies
EBP50 pep * (GGGKERAHQKRSSKRAPQMDWSKKNELFSNL) was labelled with Texas Red ® -X succinimidyl ester (Invitrogen) at the N-terminus for FP studies and was suspended in PBS buffer. The assay was carried out on black low-volume ProxiPlates (PerkinElmer, Boston, MA, U.S.A.) using a fixed concentration of 50 nM peptide and Ezrin-T567D protein concentrations ranging from 0.6 to 5000 nM in a buffer comprising 25 mM Hepes (pH 7.4), 100 mM NaCl, 0.05 % Tween 20, 0.5 mM DTT (dithiothreitol) and 0.1 % BSA. The peptide/protein mixture was incubated for 20 min in a total volume of 10 μl before analysis on an EnVision TM multiplate reader (PerkinElmer). The affinity constant was calculated from the data points with non-linear regression analysis using SigmaPlot.
GST precipitation assay
Ezrin-T567D (200 nM) was incubated in the presence or absence of 2 μM EBP50 pep * or EBP50 ctr pep * in 50 μl of pulldown buffer [20 mM Tris/HCl (pH 7.4), 300 mM NaCl, 0.1 % Triton X-100, 1 mM PMSF, 1 mM EDTA, 1 mM DTT and protease inhibitors (Complete TM tablets, Roche Diagnostics)]. GST-EBP50 (200 nM) was pre-incubated separately in 50 μl of slurry of reduced glutathione-agarose beads (containing 1 % BSA) on ice for 30 min with repeated shaking. The interaction partners were then combined and incubated on ice with repeated shaking for 2 h. The beads were washed five times in 1 ml of pulldown buffer before being boiled in SDS/PAGE sample buffer and subjected to SDS/PAGE. The gel was analysed by immunoblotting for the presence of Ezrin and GST-EBP50.
AlphaScreen (amplified luminescence proximity homogeneous assay screen) assay
All experiments were performed using 384-well white opaque plates (PerkinElmer). Except for the concentration-response curves, which were carried out on OptiPlates (PerkinElmer), all other assays were carried out on low-volume ProxiPlates. Proteins were diluted in assay buffer [25 mM Hepes (pH 7.4) and 100 mM NaCl containing 0.01 % Tween 20] at the indicated concentrations, made up to a final volume of 6 μl for the ProxiPlates and 15 μl for the OptiPlates, and incubated at room temperature (20 • C) for 30 min. Subsequently, glutathionecoated acceptor beads and streptavidin-coated donor beads (PerkinElmer), diluted in assay buffer (5 or 10 μg/ml final concentration of beads in assay) were added to a final volume of 10 μl or 25 μl. The assay plates were then incubated at room temperature for approx. 60 min before analysis on an EnVision TM multiplate reader (PerkinElmer). A concentration-response curve with the peptide antagonist (EBP50 pep * ) was obtained by 1:2 serial dilution of peptide using 6 nM GST-EBP50 and 12 nM bEzrin-T567D (biotin-labelled Ezrin-T567D) and a maximum peptide concentration of 5 μM. Owing to the light sensitivity of the beads, all assay steps were performed in subdued lighting and the incubation steps were carried out in the dark. The IC 50 values, defined as the concentration of peptide needed to inhibit the Ezrin-T567D-EBP50 binding by 50 %, were estimated by non-linear regression analyses using SigmaPlot.
Immunofluorescence analysis
Human peripheral blood was obtained from healthy donors (Oslo University Hospital Ullevaal, Blood Centre, Oslo, Norway). The present study has ethical approval and donors gave their informed consent. Primary T-cells were purified by negative selection as described previously [9] . For immunofluorescence analysis, freshly isolated T-cells were incubated with Arg 9 -EBP50 pep , Arg 9 -EBP50 ctr pep or without peptide at 37
• C for 30 min. After incubation the cells were washed in PBS and allowed to rest for 30 min on poly(L-lysine) (Sigma-Aldrich)-coated coverslips on ice. At room temperature, the cells were fixed with 3 % paraformaldehyde in PBS for 30 min, permeabilized with 0.1 % Triton X-100/PBS for 5 min, and then blocked with 2 % BSA/0.01 % Tween 20/PBS for 30 min. Primary antibodies against EBP50 (EBP-10, Abcam; diuted 1:100) and Ezrin (EZ10, described previously [27, 28] ; diluted 1:100) in 2 % BSA/0.01 % Tween 20/PBS were added for 30 min. The cells were then incubated with fluorochrome-conjugated secondary antibodies (Alexa Fluor ® 546 goat anti-mouse IgG2b and Alexa Fluor ® 488 goat anti-rabbit IgG, Molecular Probes; diluted 1:500) in 2 % BSA/0.01 % Tween 20/PBS for 30 min before being mounted on to glass microscope slides using fluorescent mounting medium (DakoCytomation). Confocal microscopy was performed with a Zeiss LSM 510 META confocal microscope with a Plan-Apochromat ×63 magnification, 1.4 oil DIC (differential interference contrast) objective lens, using laser excitation at 488 and 561 nm. The widths of the Alexa Fluor ® 488 and Alexa Fluor ® 546 emission channels were set such that bleed through across channels was negligible and images were obtained using sequential scanning. For each treatment (no peptide, Arg 9 -EBP50 pep and Arg 9 -EBP50 ctr pep ), the localization of Ezrin and EBP50 was examined in more than 100 cells from three different blood donors.
Peptide loading and stimulation of peripheral blood T-cells
Freshly isolated human primary T-cells were cultured in RPMI 1640 medium (Invitrogen) supplemented with 10 % fetal bovine serum, 100 units/ml penicillin, 1 mM pyruvate and 1× nonessential amino acids (complete medium) and loaded with 100 μM Arg 9 -peptide (EBP50 pep 
RESULTS
EBP50 and Ezrin interact with high affinity
Using a mutated form of Ezrin (Ezrin-T567D) which mimics the phosphorylated open conformation and possibly enhances EBP50 binding [25, 26] , we determined the rate and affinity constants of the Ezrin-T567D-EBP50 association. Real-time interaction analyses were carried out using SPR technology. Full-length GST-EBP50 was captured to covalently immobilized anti-GST antibody through the GST tag, as described in the Experimental section. Kinetics and affinity of binding were subsequently assessed using a range of concentrations of FPLC-purified full-length Ezrin-T567D injected over EBP50-coated surfaces ( Figure 1A) . The steady-state binding isotherm fits well to a 1:1 Langmuir binding model, with a calculated K D of 58 + − 7 nM ( Figure 1B) . Furthermore, using the BiaEvaluation software package (Biacore) to calculate association and dissociation rate constants, the binding curves of Ezrin-T567D could be fitted to a heterogeneous ligandbinding model, giving rise to two separate binding constants with coupled association and dissociation rates, indicating complex binding kinetics. This complexity could be due to the presence of two different conformational states of both proteins [29, 30] or due to some heterogeneity in the immobilized GST-EBP50. The calculated affinity constants from this model are 1.59 μM (K D1 ) and 26 nM (K D2 ), the latter being in the same range as that obtained using the steady-state 1:1 Langmuir binding model.
We next synthesized the 28-mer peptide (EBP50 pep * ) corresponding to the EB domain in EBP50 [22, 23] , with N-terminally linked Texas Red ® -X as a fluorescent probe for use in an FP assay. Binding of the fluorochrome-coupled peptide to the Ezrin protein decreases the speed of rotation of the peptide, causing polarization of the emitted light and an increase in the FP signal. Increasing concentrations of Ezrin-T567D were incubated with a fixed concentration of
Figure 1 Kinetics of the Ezrin-EBP50 interaction
(A) SPR studies were performed on an automated Biacore T100 system. FPLC-purified Ezrin-T567D was injected over a surface containing approx. 450 response units of GST-EBP50 bound to anti-GST antibody at a flow rate of 50 μl/min for 240 s. The signal from a reference surface containing GST captured to anti-GST antibody was subtracted from the response. (B) Steady-state binding isotherm using the Ezrin-binding data obtained in (A). The binding responses shown are representative of three independent experiments run on different anti-GST surfaces. The kinetics and affinity constants were calculated using the T100 BiaEvaluation software package and by non-linear regression analysis using SigmaPlot.
peptide, giving rise to a hyperbolic steady-state binding isotherm with a K D value of 95 + − 18 nM for the interaction of the EBP50 peptide with full-length Ezrin-T567D (Figure 2A) , which revealed that the affinity of the peptide for Ezrin is in the same concentration range as that of the full-length EBP50. Using the 28-mer peptide at sufficiently high concentrations, it completely abolished EBP50 binding to Ezrin in an in vitro GST precipitation assay ( Figure 2B ).
Perturbation of Ezrin-EBP50 complex formation by EBP50 pep *
To assess the interaction of Ezrin with EBP50 in solution and perturbation by the peptide further, an amplified ligand proximity homogeneous assay (AlphaScreen) was next established using bEzrin-T567D immobilized to streptavidin-coated donor beads and GST-EBP50 bound to glutathione-coated acceptor beads. Ezrin-EBP50 complex formation brought the beads in close proximity and led to a concentration-dependent chemiluminescent signal with a plateau between 12-24 nM for bEzrin-T567D and 6-12 nM for GST-EBP50 ( Figure 3A) . At higher concentrations the signal started decreasing, a phenomenon known as the 'hooking effect' [31] . The 28-mer-long EBP50 peptide competed with Ezrin-EBP50 complex formation ( Figure 3B ) and reduced the signal in a concentrationdependent manner with an IC 50 value of 185 + − 19 nM, verifying the specificity and reversibility of the interaction.
EBP50 pep displaces Ezrin, but not EBP50, from T-cell membranes
Immunofluorescence studies of the localization of Ezrin and EBP50 in human peripheral blood T-cells revealed that both proteins are localized peripherally in the proximity of the cell membrane ( Figures 4A-4C) , as also reported previously [6] and consistent with their targeting to lipid rafts. Upon treatment of resting T-cells with Arg 9 -EBP50 pep (tagged with arginine residues for cellular delivery), Ezrin was displaced from its membraneproximal localization and distributed across the cell (Figures 4D  and 4F ; note the loss of signal intensity which could be due to degradation of displaced Ezrin), whereas EBP50 remained localized to the membrane ( Figure 4E ). Treatment with a control peptide, Arg 9 neither Ezrin nor EBP50 localization ( Figures 4G-4I ). For each treatment (no peptide, Arg 9 -EBP50 pep or Arg 9 -EBP50 ctr pep ), the localization of Ezrin and EBP50 was examined in more than 100 cells from different blood donors ( Figure 4J ). In Arg 9 -EBP50 pep -treated T-cells Ezrin was displaced from its membraneproximal localization in 76 % of the examined cells, whereas it was located away from the membrane in less than 25 % of cells that received Arg 9 -EBP50 ctr pep and less than 5 % in cells that did not receive peptide (where the displacement is probably accounted for by dying cells). In contrast, EBP50 was displaced from its membrane-near localization together with Ezrin in only 16 % of the cells, showing that displacement of Ezrin is not due to general damage of the cell membrane by the peptide. In separate dualimmunofluorescence experiments Arg 9 -EBP50 pep also appeared to delocalize type I PKA (results not shown), consistent with the reported anchoring of a pool of PKA to Ezrin.
Disrupting the Ezrin-EBP50 interaction affects sensitivity of cAMP-mediated inhibition of T-cell activation
Activation of human peripheral blood T-cells by CD3/CD28 receptor co-stimulation led to the production of IL-2 which was sensitive to inhibition by increasing concentrations of 8-CPTcAMP ( Figure 5A , black bars). As depicted in Figure 5 (B), cAMP-mediated inhibition of T-cell activation is, at least in part, due to PKA-mediated phosphorylation and activation of Csk, leading to inhibiton of Lck. When cells were loaded with Arg 9 -EBP50 pep prior to T-cell activation, cAMP-mediated inhibition of IL-2 production was partially reversed at lower concentrations of cAMP (5-10 μM) as compared with cells that were treated with the same concentration of a non-binding control peptide (Arg 9 -EBP50 ctr pep ) ( Figure 5A ). Specifically, IL-2 levels increased 1.6-1.9-fold in cells treated with 100 μM Arg 9 -EBP50 pep in the presence of 5 and 10 μM cAMP respectively.
DISCUSSION
Upon stimulation of the T-cell, an IS (immunological synapse) is formed by coalescence of lipid rafts in the cell membrane and the rearrangement and recruitment of a number of signalling molecules involved in signal transmission and downstream T-cell signalling. Type I PKA is rapidly redistributed to the IS in primary T-cells during its formation where it is found in proximity of the TCR [32] . Its localization is co-ordinated by its interaction with the dual-specific AKAP Ezrin [6] . These two proteins are part of a supramolecular signalling complex, which also includes EBP50, PAG and Csk, that is crucial for positioning PKA close to its substrate Csk and mediates the inhibitory effect of cAMP on T-cell activation ( Figure 5B ). PAG interacts with the N-terminal PDZ1 domain of EBP50, whereas Ezrin interacts with a C-terminal binding site in EBP50. Interestingly, whereas PAG remains located to the IS, EBP50 dissociates from the synaptic area post-activation [19] . Ezrin is also exported out of the IS postactivation in primary T-cells [33] and appears to faciliatate the movement of type I PKA to the distal pole [6] . It is interesting to speculate whether EBP50 is also found at the distal pole in the same complex as Ezrin and PKA, and, if so, whether dissociation of EBP50 from PAG in the IS is required for migration. The importance of the PAG-EBP50-Ezrin scaffold in early T-cell signalling has not yet been fully understood, and the aim of the present study was to gain more insight into the role of the linker protein EBP50 in T-cell signalling and activation, with particular focus on its interaction with Ezrin. As already mentioned, previous studies have revealed an important role for Ezrin in anchoring type I PKA to the IS ( Figure 5B , and [6] ). The functional data from Figure 5 (A) clearly demonstrate that EBP50 also has an important role in positioning PKA close to its substrate Csk, seen as a partial reversal of the cAMP/PKA-mediated inhibition of IL-2 production when the Ezrin-EBP50 interaction is disrupted.
The dynamics of an interaction is related to the affinity of binding, involving association and dissociation rates of the complex. For the Ezrin-EBP50 interaction, an affinity constant in the nanomolar range (58 + − 7 nM) was obtained in the SPR studies, with a relatively high dissociation rate as seen from the sensorgrams (Figure 1 ). This could indicate a certain degree of dynamics in this interaction. A similar affinity (95 + − 18 nM) was obtained by FP measurements of the binding between fulllength Ezrin and a fluorochrome-coupled peptide derived from the EBP50 sequence (EBP50 pep * ) (Figure 2A ). These affinity constants are all higher than those obtained in a previous SPR study with an immobilized EBP50 peptide on the chip [23] . However, in that previous study [23] , an isolated FERM domain of the closely related Radixin was used, which, together with the experimental setup, can explain the differences. However, taken together, these separate studies all demonstrate affinities for ERM proteins to EBP50 in the nanomolar range. This relatively strong interaction could be important for holding the complex together and might indicate that Ezrin and EBP50 move away from the IS in the same complex. Furthermore, none of these molecules are anchored directly to the membrane which also facilitates transport and could explain why the PAG-EBP50 interaction is disrupted post-T-cell activation. It may be that PAG and EBP50 interact with much lower affinity than Ezrin-EBP50, therefore supporting the disruption of this complex upon T-cell activation.
The EBP50 pep used in the present work interacts specifically with Ezrin, as seen in the FP studies, whereas the AlphaScreen data demonstrate that the peptide also competes with ongoing complex formation in a specific and concentration-dependent manner (Figures 2 and 3 ). This specificity of the peptide is also clear from immunofluorescence studies of resting T-cells in which Ezrin is redistributed away from the membrane after peptide loading (Figure 4) . Taken together, these data provide us with proof of concept that the peptide actually works as a specific disruptor for the Ezrin-EBP50 complex. The peptide (EBP50 pep ) used in the present work is the native sequence corresponding to the last C-terminal part of EBP50 which has a strong affinity towards its binding partner (Figures 2 and 3, and [23] ). The affinity of the Ezrin-BP50 interaction is high. However, the rather high dissociation rate of the protein-protein complex indicates a highly dynamic interaction and may explain how the peptide gains access and why its action is relatively effective, as is evident from the IL-2 measurements and immunofluorescence studies.
Small molecules, rather than peptides, are desired for use as research tools to further elucidate biological processes in vivo in animal models or for use in therapeutic development. A starting point for developing such a compound is to perform a chemical screen using a library of SMCs (small molecular compounds). As reported in the present study, both FP and the AlphaScreen prove to be suitable assays for HTS (highthroughput screening) to search for a compound that can perturb the Ezrin-EBP50 interaction. In particular, the AlphaScreen is a robust assay that is very well suited for chemical biology screens due to its high sensitivity and strong signal-to-noise ratio (for review, see [34] ). However, in the search for an inhibitor of a biological process, the success rate is greater when targeting the active pocket of an enzyme or a receptor with an SMC rather than a protein-protein interphase. In general, protein-protein interphases quite frequently display a flat topology and many of these interphases bury a sizeable area of several hundreds of Å 2 , making the approach of finding a small molecule that perturbs the interaction a challenging task. Important determinants for affinity are energetically critical 'hot spots' for interaction which are made up of a few amino acid residues inside the dimer interphase [35] . These 'hot spots' are especially interesting when it comes to drug design and targeting. The binding of the EBP50 peptide to Radixin has been resolved crystallographically. A few residues contribute significantly to binding [23] and might be relevant 'hot spots' suitable for targeting by an SMC.
In the present work, we have uncovered an important role for EBP50 in the targeting of PKA to the synaptic region upon T-cell activation, coupling the immunomodulating cAMP-PKA-Ezrin complex to the pool of Csk anchored via PAG and controlling Lck activity. On the basis of the functional outcomes of the present study, resulting in reversibility of the inhibitory pathway when the Ezrin-EBP50 interaction is disrupted, this complex turns out to be very interesting for targeting with an SMC. 
